GlassScriptPhysician profile
Rebeka Ann Rivera
NPI 1912418377
$4,846.13
in general payments reported to CMS, 2019-2025
26 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.38 · 2022: $1,362 · 2023: $1,148 · 2024: $1,312 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,451.03 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.31 | 2022-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $573.83 | 2021-2025 | |
| Novo Nordisk INC | $563.31 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $495.12 | 2022-2024 | Xarelto |
| Amgen INC. | $418.98 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $401.43 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.66 | 2022-2025 | Jardiance |
| Edwards Lifesciences Corporation | $226.68 | 2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $190.14 | 2024-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $141.15 | 2022-2024 | Opsumit |
| Boston Scientific Corporation | $131.52 | 2022-2025 | Watchman Flx, Watchman Access System |
| Abiomed | $115.12 | 2024-2025 | Impella |
| Pfizer INC. | $98.66 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $92.39 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $72.61 | 2024-2025 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $68.43 | 2022-2025 | Nexletol |
| Cvrx, INC. | $56.20 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $35.74 | 2025 | Corevalve Evolut R |
| Glaxosmithkline, LLC. | $32.50 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $24.53 | 2025 | Cardiomems |
| Lilly USA, LLC | $22.91 | 2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $21.84 | 2022 | |
| Amryt Pharma Holdings LTD | $17.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.36 | 2023 | Edarbyclor |
| Kiniksa Pharmaceuticals International, Plc | $16.34 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeka Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.